Breast cancer study fails to lift SELLAS Life Sciences

 

• Investors seem to disappointed after SELLAS Life Sciences (SLS -34.8%) announces final data with up to 6 months follow-up from Phase 2 trial, VADIS evaluating its nelipepimut-S (NPS) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) in ductal carcinoma in situ (DCIS) of the breast.
• Preliminary data previously reported showed that treatment with even a single dose of NPS was capable of newly inducing NPS-specific cytotoxic T-lymphocytes in peripheral blood. Updated data demonstrated that CD8+ T-cell responses persist long-term post-NPS treatment.
• When compared to baseline (BL, prior to NPS administration), relative frequency of NPS-specific CD8 CTLs as a percentage (NPS-CLT%) in peripheral blood at the 1-month and 6-month post-operative time-points increased in NPS+GM-CSF group (n=9) by 11- and 14-fold: 0.01+0.02% [BL] vs. 0.11+0.12% [1-mo] and 0.14+0.12% [6-mo], respectively,
• In GM-CSF alone group (n=4), NPS-CLT% in peripheral blood increased by only 2.25- and 3.75-fold: 0.04+0.07% [BL] vs. 0.09+0.15% [1-mo] and 0.15+0.03% [6-mo], respectively.
• Relative change in NPS-CTL% mean values at 6 months post-vaccination was +1,300+450% for the NPS+GM-CSF group vs. 250+150% in the GM-CSF alone group.
• Almost all patients in both arms experienced at least mild toxicities, and the incidence of moderate toxicities was 6.7% in the GPS+GM-CSF arm and 10.7% in the GM-CSF only arm.
• https://seekingalpha.com/news/3643738-nelipepimut-s-data-from-breast-cancer-study-fails-to-lift-sellas-life-sciences